Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCLC | P48506 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 12/20 | 0.47 |
| ▸ | CPA3 | P15088 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376126 | 0.90 | GCLC (0.49) | GCLCFOLH1CPA3GRM3 | |
| SCHEMBL1376102 | 0.87 | FOLH1 (0.52) | GCLCFOLH1CPA3GRM3NAALAD2 | |
| SCHEMBL7051929 | 0.86 | FOLH1 (0.48) | GCLCFOLH1CHRM1AKR1A1CHRM3 | |
| SCHEMBL7054600 | 0.78 | FOLH1 (0.52) | GCLCFOLH1CHRM1AKR1A1CHRM3 | |
| SCHEMBL1374289 | 0.77 | FOLH1 (0.54) | FOLH1GRM3NAALAD2 | |
| SCHEMBL7054608 | 0.76 | FOLH1 (0.47) | GCLCFOLH1CHRM1AKR1A1CHRM3 | |
| SCHEMBL28925074 | 0.75 | FOLH1 (0.56) | FOLH1CPA3GRM3NAALAD2 | |
| SCHEMBL28925073 | 0.75 | FOLH1 (0.56) | FOLH1CPA3GRM3NAALAD2 | |
| SCHEMBL1374295 | 0.75 | FOLH1 (0.43) | FOLH1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL1377040 | 0.74 | CPA3 (0.62) | FOLH1CPA3ADRA1ASLC6A3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2001521512-A | — | — | 2001-11-06 | — | — | JP | claimed |
| EP-1019369-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-19 | — | — | EP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| US-5902817-A | 2-SULFINYL OR SULFONYLPENTANDIOIC ACIDS; INHIBITORS OF N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE; GLUTAMATE ABNORMALITIES; PROSTATES; ANTIEPILEPTIC AND -ISCHEMIC AGENTS; STROKES; ANALGESICS; NERVOUS SYTEM INJURIES; | GUILFORD PHARMACEUTICALS INC. (US) | 1999-05-11 | — | — | US | claimed |
| WO-1998045257-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2025-04-24 | — | — | US | disclosed |
| EP-4541378-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2025-04-03 | — | — | US | disclosed |
| CN-116059392-B | Ligand conjugate and application thereof | 同宜医药（苏州）有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1019369-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| US-5902817-A | 2-SULFINYL OR SULFONYLPENTANDIOIC ACIDS; INHIBITORS OF N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE; GLUTAMATE ABNORMALITIES; PROSTATES; ANTIEPILEPTIC AND -ISCHEMIC AGENTS; STROKES; ANALGESICS; NERVOUS SYTEM INJURIES; | GUILFORD PHARMACEUTICALS INC. (US) | 1999-05-11 | — | — | US | disclosed |
| WO-1998045257-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | GCLC 1429/4885FOLH1 1/4885CPA3 525/4885 |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | GCLC 1429/4885FOLH1 1/4885CPA3 525/4885 |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | VHL, PC, NPC1 | GCLC 1586/4885FOLH1 157/4885CPA3 1830/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | GCLC 3341/4885FOLH1 1/4885CPA3 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.